Aeterna up on SPA for Phase III for AEZS-108

Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS) gained C$0.33 (15%) to C$2.49 on Friday after it said it reached an agreement with FDA on an SPA for a Phase III trial of AEZS-108 for endometrial cancer. On NASDAQ, the stock was up $0.30 (14%) to $2.47. The open-label trial will enroll about 500 patients to compare AEZS-108, a doxorubicin chemotherapeutic conjugated to a luteinizing hormone-releasing hormone (LHRH) receptor agonist, with doxorubicin as second-line therapy for locally advanced, recurrent or metastatic endometrial cancer. The primary endpoint will be median overall survival (OS). The compound is also in Phase II testing for prostate, breast and bladder cancer. Aeterna could not be reached for details. ...